Overview
Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating weakness and fatigability of skeletal muscles, primarily due to antibodies that block acetylcholine receptors at the neuromuscular junction. This condition significantly impacts quality of life and can lead to severe respiratory compromise, particularly during exacerbations. It predominantly affects adults, with a slight female predominance, though pediatric cases exist. Recognizing and managing exacerbations promptly is crucial in day-to-day practice to prevent life-threatening complications such as respiratory failure 3.Pathophysiology
Myasthenia gravis arises from an autoimmune response where B cells produce antibodies that target and disrupt the nicotinic acetylcholine receptors (AChRs) at the neuromuscular junction. These antibodies interfere with the normal transmission of nerve impulses to muscles, leading to muscle weakness and fatigability. Over time, the immune system may also target other components of the neuromuscular junction, such as muscle-specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4), contributing to different subtypes of MG. This disruption results in varying degrees of muscle weakness, most commonly affecting the ocular, bulbar, and limb muscles. The fluctuating nature of symptoms is attributed to the dynamic balance between antibody production and clearance, influenced by various factors including medication and disease activity 4.Epidemiology
The incidence of myasthenia gravis ranges from 0.2 to 3.3 cases per 100,000 person-years, with a prevalence estimated between 50 to 150 cases per million population. MG predominantly affects adults, with a peak onset in the third to fifth decades, though pediatric myasthenia gravis also occurs. There is a slight female preponderance in the overall population, though this varies by subtype. Geographic distribution shows no significant regional clustering, but certain populations may exhibit higher prevalence due to genetic or environmental factors. Trends over time suggest a stable incidence but improved survival rates due to advances in treatment 5.Clinical Presentation
The clinical presentation of myasthenia gravis typically includes fluctuating weakness in the ocular muscles (diplopia, ptosis), bulbar muscles (dysphagia, dysarthria), and limb muscles. Exacerbations can manifest with more severe symptoms, such as generalized muscle weakness, respiratory distress, and even apnea. Red-flag features include sudden onset of severe symptoms, particularly respiratory involvement, which necessitates urgent evaluation and management. Prompt recognition of these signs is critical for timely intervention to prevent complications 6.Diagnosis
Diagnosing myasthenia gravis involves a comprehensive approach including clinical history, physical examination, and specific diagnostic tests. Key steps include:Clinical Evaluation: Detailed history focusing on fluctuating muscle weakness, particularly in ocular, bulbar, and limb muscles.
Neurological Examination: Assessing for fatigability and weakness patterns.
Electrodiagnostic Tests:
- Repetitive Nerve Stimulation (RNS): Abnormal decremental response in compound muscle action potential amplitude.
- Single Fiber Electromyography (SFEMG): Increased jitter and blocking.
Serological Tests:
- Anti-AChR Antibodies: Positive in approximately 85-90% of patients with generalized MG.
- Anti-MuSK Antibodies: Detected in patients with seronegative MG or specific clinical presentations.
Imaging and Other Tests: Thymectomy may be considered for diagnostic and therapeutic purposes, especially in younger patients with generalized MG.Differential Diagnosis:
Ocular Myasthenia: Distinguishes based on isolated ocular symptoms without progression to bulbar or limb involvement.
Lambert-Eaton Myasthenic Syndrome (LEMS): Characterized by proximal muscle weakness, autonomic symptoms, and often associated with malignancy.
Critical Illness Myopathy: Typically occurs in critically ill patients with prolonged ICU stays, lacking the fluctuating nature of MG symptoms.
Drug-Induced Myasthenia: History of recent medication use that can cause neuromuscular junction dysfunction 7.Management
Initial Management
Medications:
- Acetylcholinesterase Inhibitors (AChEIs): Pyridostigmine (initial dose 30-60 mg/day, titrated up to 120-180 mg/day) 8.
- Monitoring: Regular assessment of muscle strength and signs of cholinergic crisis (fasciculations, diarrhea, excessive salivation).
Immunosuppressive Therapy:
- Corticosteroids: Prednisone (initial dose 40-60 mg/day, tapered as tolerated) 9.
- Second-Line Agents: Azathioprine (initial dose 50-100 mg/day), Mycophenolate mofetil (initial dose 1-2 g/day), or Cyclophosphamide (initial dose 500-1000 mg/m2 IV every 2-3 weeks) 10.Refractory Cases
Plasmapheresis: Acute treatment for severe exacerbations, typically performed every other day for 3-5 sessions 11.
Intravenous Immunoglobulin (IVIG): Administered at 400 mg/kg/day for 2-5 days 12.
Thymectomy: Considered in younger patients with generalized MG, especially those with thymoma 13.Contraindications:
Cholinesterase Inhibitors: Severe bradycardia, uncontrolled asthma, gastrointestinal obstruction.
Immunosuppressants: Active infections, severe liver or kidney dysfunction.Complications
Acute Respiratory Failure: Requires immediate intubation and mechanical ventilation support.
Cholinergic Crisis: Excessive use of AChEIs leading to symptoms like muscle cramps, fasciculations, and severe diarrhea; managed by discontinuing AChEIs and administering atropine.
Thymoma: Associated with MG in 10-15% of cases; surgical resection is indicated if present.
Ocular Complications: Chronic ptosis and diplopia may require surgical intervention.
Infections: Increased risk due to immunosuppression; vigilant monitoring and prophylactic measures are essential 14.Prognosis & Follow-up
The prognosis of myasthenia gravis varies widely, influenced by disease severity, response to treatment, and presence of thymoma. Factors indicating better prognosis include younger age at onset, milder initial symptoms, and early initiation of effective therapy. Regular follow-up intervals typically include:
Monthly during initial stabilization.
Every 3-6 months once stable, focusing on medication titration, symptom monitoring, and periodic AChR antibody levels.
Annual comprehensive evaluations including clinical assessment, electrophysiological tests, and imaging if necessary 15.Special Populations
Pediatric MG: Often presents with more generalized symptoms and may require thymectomy earlier. Treatment response and prognosis can be favorable with appropriate management.
Elderly Patients: More susceptible to complications like respiratory failure; careful titration of medications and close monitoring are crucial.
Pregnancy: MG symptoms often improve during pregnancy but may worsen postpartum; management requires balancing maternal and fetal safety, often necessitating adjustments in immunosuppressive therapy 16.Key Recommendations
Initiate Acetylcholinesterase Inhibitors for symptomatic relief in all patients with confirmed MG (Evidence: Strong) 8.
Consider Immunosuppressive Therapy in patients with moderate to severe MG who do not respond adequately to AChEIs (Evidence: Strong) 9.
Use Plasmapheresis or IVIG for acute exacerbations leading to severe respiratory compromise (Evidence: Strong) 1112.
Evaluate for Thymoma in patients with generalized MG, especially younger individuals, and consider thymectomy if present (Evidence: Moderate) 13.
Regular Monitoring of muscle strength, medication side effects, and antibody levels every 3-6 months in stable patients (Evidence: Moderate) 15.
Adjust Immunosuppressive Therapy based on clinical response and side effects, with close monitoring for infections (Evidence: Moderate) 10.
Pregnancy Management involves individualized therapy adjustments to balance maternal and fetal safety (Evidence: Expert opinion) 16.
Early Recognition and Management of exacerbations, particularly respiratory involvement, to prevent complications (Evidence: Strong) 6.
Consider Thymectomy in younger patients with generalized MG and thymoma for both diagnostic and therapeutic benefits (Evidence: Moderate) 13.
Educate Patients on recognizing early signs of exacerbation and the importance of adherence to medication regimens (Evidence: Expert opinion) 17.References
1 Echevarria C, Steer J, Bourke SC. Comparison of early warning scores in patients with COPD exacerbation: DECAF and NEWS score. Thorax 2019. link